Sermorelin

Mechanism

Promotes pulsatile GH release from the pituitary with modest IGF-1 rise.

Reported effects

What sources associate with this compound. Reported categories, not outcomes we have graded — each would need its own citation and rung.

• Sleep quality
• Recovery support
• Body-composition support

Reconstitution

mass ÷ diluent = concentration; dose ÷ concentration = volume; volume × the syringe factor = units on the barrel (100 for U-100, 40 for U-40). Run your own numbers.

Half-life, storage & sport

Elimination half-life

4.3 +/- 1.4 minutes (human, IV) — study. GHRH(1-29)-NH2 in normal men, J Clin Endocrinol Metab 1994.

Storage

Lyophilised: Stable at room temperature ~3 weeks; store desiccated below -18C. Reconstituted: 4C for 2-7 days; below -18C for future use; 0.1% HSA/BSA for long term; avoid freeze-thaw. — source. ProSpec GHRH Human (Sermorelin, 1-29) technical datasheet. Supplier handling recommendation for research-grade lyophilate, not a per-compound stability study.

In sport (WADA 2026)

Prohibited, at all times — named S2.2.4 (GHRH analogues). the list

The half-life on file is 4 min, measured intravenously. On the schedule this record states — daily — each dose has fallen to under 0.1% of its own peak by the time the next is given. Nothing accumulates, and there is no loading phase to run.

The half-life was measured by a route this is not given by. That makes it a lower bound rather than an estimate: absorption from an injection site goes on supplying the blood after an intravenous bolus would have cleared, so the real curve is flatter and lasts longer than the one drawn here. It is never shorter.

The rise is not modelled and the axis is not a blood level. No absorption rate constant and no volume of distribution are on file, so each dose appears at full height the instant it is given, and the axis is percent of this compound's own peak.

Literature on file 3

• review or editorial
  Sermorelin: A better approach to management of adult-onset growth hormone insufficiency? (Clinical Interventions in Aging 2006, cited 8x) graded on: indexed as "Editorial" - secondary literature, not a study — “Editorial”
• human RCT
  FDA approval NDA019863, NDA020443 graded on: an FDA approval (NDA019863, NDA020443), which requires adequate and well-controlled human investigations — “NDA019863, NDA020443”

Not graded

1 citation whose study design could not be read from the title. Left ungraded rather than guessed at.

• not graded
  Sermorelin (BioDrugs 1999, cited 29x)

What is circulated not evidence 3

Claims passed around in community guides and vendor copy, recorded because they circulate — not because they are true. Each is shown with the page it was read from and what this record actually holds. Checked 2026-08-24.

• unverified community data dose ubiquitous agrees with the record

  200-300 mcg once nightly by subcutaneous injection, 30-60 minutes before bed on an empty stomach, is circulated as the standard protocol.

  Most research-context protocols use 200-300 mcg once a night, by subcutaneous injection

  On the record Dosing on file is 200-500 mcg daily; the circulated band sits inside it, but the bedtime timing and fasting rules have no record.

  Source 1 · Source 2

• unverified community data timing common nothing on file either way

  A 5-on/2-off weekly schedule is circulated, justified as preventing receptor desensitisation.

  5 on / 2 off: Sunday-Thursday on, Friday-Saturday off

  On the record No desensitisation or intermittent-schedule record exists on file for sermorelin.

  Source 1

• unverified community data benefit common nothing on file either way

  Sleep and recovery improvements within 2-4 weeks and body-composition change over 3-6 months are circulated as the expected timeline.

  Sleep and recovery changes often appear in 2-4 weeks. Body-composition shifts usually need 3-6 months.

  On the record Benefits on file are sleep quality, recovery support and body-composition support; no time-to-effect record exists.

  Source 1

Identity

PubChem CID 16132413 computed 3D conformer

Skeletal formulathe canonical depiction

Drawn by PubChem from CID 16132413, the identifier on this record.

Molecular weight

3357.9

Molecular formula

C149H246N44O42S

CAS number

86168-78-7

PubChem CID

16132413

InChI key

WGWPRVFKDLAUQJ-MITYVQBRSA-N

Sequence

YADAIFTNSYRKVLGQLSARKLLQDIMSR

SMILES

CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CC3=CC=C(C=C3)O)N

InChI

InChI=1S/C149H246N44O42S/c1-20-77(13)116(191-122(211)81(17)168-132(221)104(66-113(204)205)178-121(210)79(15)167-123(212)88(152)62-84-39-43-86(198)44-40-84)145(234)185-102(63-83-32-23-22-24-33-83)138(227)193-118(82(18)197)146(235)186-103(65-111(155)202)137(226)189-108(71-196)142(231)182-101(64-85-41-45-87(199)46-42-85)136(225)175-93(38-31-56-165-149(161)162)126(215)174-91(35-26-28-53-151)131(220)190-115(76(11)12)143(232)184-97(58-72(3)4)124(213)166-68-112(203)170-94(47-49-109(153)200)128(217)180-100(61-75(9)10)135(224)188-106(69-194)140(229)169-80(16)120(209)172-92(37-30-55-164-148(159)160)125(214)173-90(34-25-27-52-150)127(216)179-99(60-74(7)8)134(223)181-98(59-73(5)6)133(222)176-95(48-50-110(154)201)129(218)183-105(67-114(206)207)139(228)192-117(78(14)21-2)144(233)177-96(51-57-236-19)130(219)187-107(70-195)141(230)171-89(119(156)208)36-29-54-163-147(157)158/h22-24,32-33,39-46,72-82,88-108,115-118,194-199H,20-21,25-31,34-38,47-71,150-152H2,1-19H3,(H2,153,200)(H2,154,201)(H2,155,202)(H2,156,208)(H,166,213)(H,167,212)(H,168,221)(H,169,229)(H,170,203)(H,171,230)(H,172,209)(H,173,214)(H,174,215)(H,175,225)(H,176,222)(H,177,233)(H,178,210)(H,179,216)(H,180,217)(H,181,223)(H,182,231)(H,183,218)(H,184,232)(H,185,234)(H,186,235)(H,187,219)(H,188,224)(H,189,226)(H,190,220)(H,191,211)(H,192,228)(H,193,227)(H,204,205)(H,206,207)(H4,157,158,163)(H4,159,160,164)(H4,161,162,165)/t77-,78-,79-,80-,81-,82+,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,115-,116-,117-,118-/m0/s1

Classified as

GHRH Receptor Agonismmechanism

Most records filed under the growth hormone heading act either here or at the ghrelin receptor, and knowing which one tells you what a study actually measured: the pituitary's output, not a hormone that was injected.

Growth Hormone / IGF-1 Axispathway

The lab value people actually track, IGF-1 in ng/mL, sits two steps downstream of where most of these compounds act, so a record's mechanism and its measurable marker are rarely the same thing.

Subcutaneousroute

This is the route the reconstitution arithmetic assumes. Mass divided by diluent volume gives concentration, dose divided by concentration gives volume, and volume in mL multiplied by 100 gives units on a U-100 barrel: 5 mg in 2 mL is 2.5 mg/mL, and 0.25 mg comes out at 0.1 mL, which is 10 units.

Also called

• Sermorelin

Listed prices 240

What 151 shops we track listed for Sermorelin, read from their own public catalogues on 2026-09-14. We take no commission on these and they are not ranked by any payment — how vendors are scored.

Share this record